PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14719841

Maternal immunization.

Stanley A Gall
View original source ↗Export metadata ↓

Abstract

Maternal immunization embraces the concepts that vaccines given to pregnant women enhance their resistance to vaccine-preventable diseases and passive antibodies that cross the placenta protect the neonate for the first 3 to 6 months of life. It is a great public health move to get excellent protection at a small cost. Because all recommended vaccines for use in pregnancy are safe, it makes good sense to bring patients up to date on vaccines.

Explore related subjects

Chickenpox VaccineDiphtheria-Tetanus VaccineFemaleHepatitis A VaccinesHepatitis B VaccinesHumansImmunizationInfluenza, HumanMeasles-Mumps-Rubella VaccineMeningococcal VaccinesPneumococcal VaccinesPoliovirus VaccinesPregnancyPregnancy Complications, InfectiousYellow Fever VaccineJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Stanley A Gall. 2003. Maternal immunization.. https://doi.org/10.1016/s0889-8545(03)00085-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

[Papillomavirus diseases].

Papillomaviruses are prevalent throughout the world. They can cause warts or papillomas. Some papillomaviruses are also involved in the pathogenesis of malignant tumors. Cutaneous and anogenital warts are the most frequent viral disease of the skin. The incidence of verrucae vulgaris and condylomata is estimated to be 7-10% in the European population and 1% in the American population. HPV infections can be verified by clinical examination, cytology and histology, detection of antibodies, molecular techniques and directly via viral structures. Antibodies against HPV are considered markers for prolonged infection and cumulatively high expression of viral particles since they persist with low titers years after a lesion has resolved. Sensitivity only reaches 50-60% even in HPV DNA-positive patients. Serodiagnosis does not appear to be appropriate for routine practice. No virustatic treatment exists. Depending on wart-specific factors, compliance of the patient, and experience of the attending therapist, all ablative, chemodestructive or novel immuno modulatory procedures are comparable. However, there are enormous differences in price and effort required for treatment, which should be considered when choosing the method.

Chickenpox Vaccine↗
PubMed2004

New method of differentiating wild-type varicella-zoster virus (VZV) strains from Oka varicella vaccine strain by VZV ORF 6-based PCR and restriction fragment length polymorphism analysis.

A new method was developed to distinguish accurately wild-type varicella-zoster virus (VZV) strains from the Oka vaccine strain. Several DNA fragments covering open reading frame (ORF) 1-37 were amplified from wild-type VZV strains including the Oka parent strain and from the Oka vaccine strain. Restriction fragment length polymorphisms of these regions were compared, and nucleotide differences between the vaccine virus and other wild-type VZV strains were noted in ORFs 6, 10, and 35. In addition, variations of the R2 and R4 reiterated structures of the vaccine and its parent strains were examined. The Oka vaccine strain used in Japan was shown to be a mixture of viruses with different nucleotide sequences that had variations in at least three nucleotide positions in ORF 1-37 and had variable polymorphisms at R2 and R4 repeat regions (two and three patterns, respectively). The Oka parent strain on the other hand showed a single sequence and had only one reiterated structure at these regions. When VZV ORF 6 was amplified and its product was digested with AluI, the Oka vaccine strain could be precisely differentiated from its parent and from 56 other Japanese clinical isolates.

Chickenpox Vaccine↗
PubMed2004

Use of the false discovery rate for evaluating clinical safety data.

Clinical adverse experience (AE) data are routinely evaluated using between group P values for every AE encountered within each of several body systems. If the P values are reported and interpreted without multiplicity considerations, there is a potential for an excess of false positive findings. Procedures based on confidence interval estimates of treatment effects have the same potential for false positive findings as P value methods. Excess false positive findings can needlessly complicate the safety profile of a safe drug or vaccine. Accordingly, we propose a novel method for addressing multiplicity in the evaluation of adverse experience data arising in clinical trial settings. The method involves a two-step application of adjusted P values based on the Benjamini and Hochberg false discovery rate (FDR). Data from three moderate to large vaccine trials are used to illustrate our proposed 'Double FDR' approach, and to reinforce the potential impact of failing to account for multiplicity. This work was in collaboration with the late Professor John W. Tukey who coined the term 'Double FDR'.

Chickenpox Vaccine↗